n = 42 | |
---|---|
Gender, m/f (ratio) | 23/19 (1.21) |
Age (average ± SD) | 70.5 ± 11.44 |
BMI (average ± SD) | 23.97 ± 5.23 |
Metastatic disease, n (%) | 21 (50) |
Intra-abdominal metastasis | 14 (33.3) |
Liver metastasis | 10 (23.8) |
Extra-abdominal metastasis | 2 (4.7) |
Locally advanced disease only, n (%) | 21 (50) |
Comorbidities, n (%) | |
HTN | 24 (57.14) |
DM | 17 (40.4) |
HPL | 17 (40.4) |
IHD | 9 (21.4) |
CHF | 2 (4.7) |
CKD | 3 (7.14) |
CVA | 4 (9.4) |
BPH | 3 (7.14) |
COPD | 1 (2.35) |
Smoking | 10 (23.8) |
Obesity | 3 (7.14) |
Past abdominal surgery, n (%) | 10 (23.8) |
Preop chemotherapy, n (%) | 13 (30.9) |
Preop PTD, n (%) | 4 (9.4) |
Preop ERCP, n (%) | 11 (26.2) |
Preop surgical exploration, n (%) | 5 (11.9) |
Preop albumin (mean ± SD) | 34.6 ± 4.94 |
Preop albumin< 30, n (%) | 6 (14.28) |
Preop bilirubin> 1, n (%) | 14 (33.3) |